These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 28111263)

  • 21. Current evidence on the health-beneficial effects of berry fruits in the prevention and treatment of metabolic syndrome.
    Kowalska K; Olejnik A
    Curr Opin Clin Nutr Metab Care; 2016 Nov; 19(6):446-452. PubMed ID: 27583706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physical activity for the prevention and treatment of metabolic disorders.
    Montesi L; Moscatiello S; Malavolti M; Marzocchi R; Marchesini G
    Intern Emerg Med; 2013 Dec; 8(8):655-66. PubMed ID: 23657989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of Metabolic Syndrome in Children.
    Tagi VM; Samvelyan S; Chiarelli F
    Horm Res Paediatr; 2020; 93(4):215-225. PubMed ID: 33017828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging Targets to Relieve Fat Stress-Induced Liver Diseases: UDCA, Tocotrienol, ω-3 PUFAs, and IgY Targeted NPC1L1 Cholesterol Transporter.
    Cha JY; Park JM; Lee HJ; Bae JS; Han YM; Oh BC; Ko KH; Hahm KB
    Curr Pharm Des; 2017; 23(27):3941-3951. PubMed ID: 28714405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds.
    Rochlani Y; Pothineni NV; Kovelamudi S; Mehta JL
    Ther Adv Cardiovasc Dis; 2017 Aug; 11(8):215-225. PubMed ID: 28639538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of pharmacotherapy in the prevention and treatment of paediatric metabolic syndrome--Implications for long-term health: part of a series on Pediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni.
    Sabin MA; Magnussen CG; Juonala M; Cowley MA; Shield JP
    Pharmacol Res; 2012 Apr; 65(4):397-401. PubMed ID: 22037094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased prevalence and risk of non-alcoholic fatty liver disease in overweight and obese patients with Type 2 diabetes in South China.
    Yi M; Chen RP; Yang R; Chen H
    Diabet Med; 2017 Apr; 34(4):505-513. PubMed ID: 27334577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups.
    ; Lonardo A; Bellentani S; Argo CK; Ballestri S; Byrne CD; Caldwell SH; Cortez-Pinto H; Grieco A; Machado MV; Miele L; Targher G
    Dig Liver Dis; 2015 Dec; 47(12):997-1006. PubMed ID: 26454786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonalcoholic Fatty Liver Disease in Children: Hepatic and Extrahepatic Complications.
    Selvakumar PKC; Kabbany MN; Nobili V; Alkhouri N
    Pediatr Clin North Am; 2017 Jun; 64(3):659-675. PubMed ID: 28502444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiology of paediatric metabolic syndrome and type 2 diabetes mellitus.
    De Ferranti SD; Osganian SK
    Diab Vasc Dis Res; 2007 Dec; 4(4):285-96. PubMed ID: 18158698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.
    Jeanes YM; Reeves S
    Nutr Res Rev; 2017 Jun; 30(1):97-105. PubMed ID: 28222828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-alcoholic fatty pancreas disease.
    Alempijevic T; Dragasevic S; Zec S; Popovic D; Milosavljevic T
    Postgrad Med J; 2017 Apr; 93(1098):226-230. PubMed ID: 28069746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Mechanism Analysis and Prevention of Pathogenesis of Nonalcoholic Steatohepatitis].
    Nakajima T; Naito H
    Nihon Eiseigaku Zasshi; 2015; 70(3):197-204. PubMed ID: 26411937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of free fatty acids in the inflammatory and cardiometabolic profile in adolescents with metabolic syndrome engaged in interdisciplinary therapy.
    Masquio DC; de Piano-Ganen A; Oyama LM; Campos RM; Santamarina AB; de Souza GI; Gomes AD; Moreira RG; Corgosinho FC; do Nascimento CM; Tock L; Tufik S; de Mello MT; Dâmaso AR
    J Nutr Biochem; 2016 Jul; 33():136-44. PubMed ID: 27155920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics of obesity and its related disorders in China.
    Jia WP; Wang C; Jiang S; Pan JM
    Biomed Environ Sci; 2010 Feb; 23(1):4-11. PubMed ID: 20486430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A constellation of complications: the metabolic syndrome.
    Grundy SM
    Clin Cornerstone; 2005; 7(2-3):36-45. PubMed ID: 16473259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A concise review of non-alcoholic fatty liver disease.
    Than NN; Newsome PN
    Atherosclerosis; 2015 Mar; 239(1):192-202. PubMed ID: 25617860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Insights in the Metabolic Syndrome in Childhood and Adolescence.
    Bussler S; Penke M; Flemming G; Elhassan YS; Kratzsch J; Sergeyev E; Lipek T; Vogel M; Spielau U; Körner A; de Giorgis T; Kiess W
    Horm Res Paediatr; 2017; 88(3-4):181-193. PubMed ID: 28848168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNAs in obesity-associated disorders.
    Abente EJ; Subramanian M; Ramachandran V; Najafi-Shoushtari SH
    Arch Biochem Biophys; 2016 Jan; 589():108-19. PubMed ID: 26416722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.